X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA FRESENIUS KABI ONCO. PLETHICO PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x -1.1 22.1 - View Chart
P/BV x 0.0 3.1 0.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
PLETHICO PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs395176 224.4%   
Low Rs3179 39.9%   
Sales per share (Unadj.) Rs604.437.7 1,603.8%  
Earnings per share (Unadj.) Rs32.55.1 637.7%  
Cash flow per share (Unadj.) Rs51.36.7 763.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.642.5 1,113.1%  
Shares outstanding (eoy) m34.08158.23 21.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.4 10.4%   
Avg P/E ratio x6.625.0 26.3%  
P/CF ratio (eoy) x4.218.9 21.9%  
Price / Book Value ratio x0.53.0 15.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,26220,135 36.1%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m1,596703 227.0%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m20,5985,963 345.4%  
Other income Rs m38618 2,146.3%   
Total revenues Rs m20,9845,981 350.8%   
Gross profit Rs m2,8181,430 197.0%  
Depreciation Rs m642258 249.1%   
Interest Rs m1,593-26 -6,127.7%   
Profit before tax Rs m9691,216 79.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m-138342 -40.4%   
Profit after tax Rs m1,107806 137.3%  
Gross profit margin %13.724.0 57.0%  
Effective tax rate %-14.328.1 -50.8%   
Net profit margin %5.413.5 39.8%  
BALANCE SHEET DATA
Current assets Rs m18,8775,102 370.0%   
Current liabilities Rs m11,8962,385 498.7%   
Net working cap to sales %33.945.6 74.4%  
Current ratio x1.62.1 74.2%  
Inventory Days Days36150 24.0%  
Debtors Days Days198113 174.6%  
Net fixed assets Rs m9,8615,148 191.5%   
Share capital Rs m341158 215.4%   
"Free" reserves Rs m12,3316,556 188.1%   
Net worth Rs m16,1396,732 239.7%   
Long term debt Rs m4,706952 494.2%   
Total assets Rs m33,14610,388 319.1%  
Interest coverage x1.6-45.8 -3.5%   
Debt to equity ratio x0.30.1 206.1%  
Sales to assets ratio x0.60.6 108.3%   
Return on assets %8.17.5 108.5%  
Return on equity %6.912.0 57.3%  
Return on capital %12.314.6 84.2%  
Exports to sales %21.474.5 28.7%   
Imports to sales %15.224.8 61.4%   
Exports (fob) Rs m4,4024,441 99.1%   
Imports (cif) Rs m3,1361,477 212.3%   
Fx inflow Rs m4,4025,298 83.1%   
Fx outflow Rs m3,1841,772 179.7%   
Net fx Rs m1,2193,525 34.6%   
CASH FLOW
From Operations Rs m2,4371,274 191.3%  
From Investments Rs m-6,265-1,204 520.2%  
From Financial Activity Rs m2,490-196 -1,269.8%  
Net Cashflow Rs m-1,337-126 1,058.7%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 4.3 0.3 1,433.3%  
FIIs % 5.5 9.6 57.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 9.1 82.4%  
Shareholders   10,665 42,599 25.0%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS